bamlanivimab and etesevimab

Bamlanivimab and Etesevimab: EUA in India

On 2 June 2021, the antibody-drug combination by the US drugmaker Eli Lilly was granted EUA[1] in India. This combination was permitted for the treatment of mild to moderate COVID -19 in India.

The monoclonal antibody drugs, bamlanivimab 700 mg, and etesevimab 1400 mg, have received permission for restricted use. Eli Lilly has stated that these two drugs are used together for treating mild to moderate patients. [2]

The company is in talks with the Indian government and regulatory authorities to donate these two drugs to India. By doing so, the drug firm hopes to speed up access and provide treatment to all the patients in the country.

Bamlanivimab and etesevimab: This antibody combination has also received the EUA in the US and some European Union countries for treating COVID – 19.

In May 2021, Eli Lilly had received permission for the emergency use of barcitinib in combination with remdesivir. This combination was permitted for treating suspected or laboratory – confirmed COVID – 19 in India.

Abbreviations : 1. Emergency Use Authorization

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top